The Shifting ATTR-CM Landscape: Early Diagnosis, Emerging Therapies & Personalized Care
Pablo Garcia-Pavia, MD, PhD
Francesco Cappelli, MD
ns-MRAs and eGFR Slope: The Kidney Perspective
Csaba P. Kovesdy, MD
Finnian R. McCausland, MD
ns-MRAs: The Cardiovascular-Kidney-Metabolic Connection
FCS and SHTG: Are We Meeting the Need?
Ira J. Goldberg, MD
Kausik Ray, MBChB, MD, MPhil
Christie Ballantyne, MD
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
Akshay S. Desai, MD
John McMurray, MD
Mastering MRA Monitoring: The Key to Success
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
Gianluigi Savarese, MD
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
James Burton, DM, FRCP
Aaron Wong, MD
Reaching LDL-c targets in patients at high CV risk: How well are we doing?
Julia Brandts, MD
Novel oral LDL-c lowering therapies on the horizon: CETP inhibition
Ulrich Laufs, MD, PhD
The case for early LDL-c lowering in patients at increased CV risk: When should we start?
Pasquale Perrone-Filardi, MD, PhD
The remaining challenges in lowering LDL-c in patients at increased CV risk
Prof. Kausik Ray
Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes
Summarizing multidisciplinary strategies: Where do we go from here?
Clinical choices in managing LDL-c: Where do novel therapies fit in?
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Carolyn S. P. Lam, MBBS, PhD
Scott Solomon, MD
Mikhail Kosiborod, MD
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.